|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Alaunos_Therapeutics
|
|
gptkbp:ceo
|
gptkb:Franz-Werner_Haas
|
|
gptkbp:clinical_trial
|
Phase 1
Phase 2
Phase 3
COVID-19 vaccine trial
cancer vaccine trial
rare disease trial
|
|
gptkbp:collaborations
|
gptkb:Bill_&_Melinda_Gates_Foundation
gptkb:CEPI
gptkb:Harvard_University
gptkb:University_of_Pennsylvania
|
|
gptkbp:focus
|
m RNA technology
|
|
gptkbp:founded
|
gptkb:2000
|
|
gptkbp:founder
|
gptkb:Ingmar_Hoerr
|
|
gptkbp:headquarters
|
gptkb:Tübingen,_Germany
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Cure Vac N. V.
|
|
gptkbp:industry
|
gptkb:drug
|
|
gptkbp:invention
|
m RNA delivery systems
m RNA vaccine formulations
m RNA stabilization
m RNA therapeutic applications
|
|
gptkbp:investment
|
$100 million
|
|
gptkbp:ipo
|
gptkb:2020
|
|
gptkbp:market_cap
|
$1 billion
|
|
gptkbp:notable_products
|
C Vn Co V
|
|
gptkbp:partnership
|
gptkb:Eli_Lilly
gptkb:GSK
gptkb:temple
gptkb:Zymeworks
gptkb:Sanofi
gptkb:Bayer_AG
gptkb:Boehringer_Ingelheim
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer
gptkb:Moderna
gptkb:Roche
gptkb:Amgen
gptkb:Sana_Biotechnology
gptkb:Novartis
gptkb:Takeda
gptkb:Astellas
gptkb:Cure_Vac_Biologics
Merck K Ga A
|
|
gptkbp:research_areas
|
gptkb:Tübingen
gptkb:Boston
vaccines
therapeutics
|
|
gptkbp:research_focus
|
gptkb:healthcare_organization
gptkb:COVID-19
rare diseases
|
|
gptkbp:stock_exchange
|
gptkb:NASDAQ
|
|
gptkbp:subsidiary
|
gptkb:Cure_Vac_AG
|
|
gptkbp:symbol
|
CVAC
|
|
gptkbp:technology
|
m RNA vaccines
m RNA therapeutics
|
|
gptkbp:website
|
www.curevac.com
|
|
gptkbp:bfsParent
|
gptkb:Ariad_Pharmaceuticals
gptkb:Soft_Bank_Group_Corporation
gptkb:Cure_Vac_AG
|
|
gptkbp:bfsLayer
|
4
|